There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2+ breast cancer (BC). The aim of this study was to assess the impact of local and systemic treatments on the outcome of patients diagnosed with BM from HER2+ BC over a period of 10 years, from 2005 to 2014.
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer
Alongi F.;
2019-01-01
Abstract
There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2+ breast cancer (BC). The aim of this study was to assess the impact of local and systemic treatments on the outcome of patients diagnosed with BM from HER2+ BC over a period of 10 years, from 2005 to 2014.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
herba2019.pdf
solo utenti autorizzati
Tipologia:
Full Text
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
723.75 kB
Formato
Adobe PDF
|
723.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
